This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Align Technology, based in California, manufactures and markets a system of clear aligner therapy, intra-oral scanners and CAD/CAM (computer-aided design and computer-aided manufacturing) digital services used in dentistry, orthodontics, and dental records storage. The clear aligner system corrects malocclusion using nearly invisible and removable appliances that gently move the tooth to a desired final position.
BioScrip's Infusion Business Strong, Dull 2017 View a Drag
by Zacks Equity Research
BioScrip's (BIOS) progressive CORE plan should enhance its financial position. However, the company's 2017 outlook loses steam based on an anticipated adverse impact of Cures Act legislation.
Stryker (SYK) to Gain From Solid Portfolio and Acquisitions
by Zacks Equity Research
Stryker's (SYK) diverse product portfolio alongside acquisition-driven strategy would continue to boost growth prospects. However, competition in the Chinese market raise concern.
Zimmer (ZBH) Plagued by Various Internal and External Issues
by Zacks Equity Research
Zimmer Biomet (ZBH) continues to suffer a bad patch, entangled with issues including its decade-old CEO's recent exit post a dull earnings season due to poor knee business.
Myriad Genetics' EndoPredict Gets Positive Coverage Decision
by Zacks Equity Research
Considering Myriad Genetics' (MYGN) EndoPredict has been used clinically in more than 15,000 patients, we are confident about the growing adaptability of this test post the Medicare coverage approval.
Walgreens Boots to Gain From Altered Rite Aid Deal, Alliance
by Zacks Equity Research
The new acquisition deal with Rite Aid would enable Walgreens (WBA) to buy nearly half of its business at a deal value, almost one-third of the original price. Downsides remain a challenge.
Fluidigm (FLDM) Licenses CFTR Assay From Baylor Genetics
by Zacks Equity Research
Fluidigm (FLDM) has licensed rights to commercialize the cystic fibrosis transmembrane conductance regulator. The company is focused on improving its Juno automated microfluidic system.
Allscripts, Elligo Health Enter in Strategic Partnership
by Zacks Equity Research
Allscripts' (MDRX) Strategic Partnership with Elligo Health would aid the company in capturing the Clinical Research Organizations' lucrative market.
Walgreens' (WBA) Research Website to Add Value in Healthcare
by Zacks Equity Research
Walgreens Boots Alliance's (WBA) Center for Health & Wellbeing Research is set to improve patient care and outcomes while reducing health care costs at the same time.
Omnicell Upgrades Web Portal, Grows in Medication Management
by Zacks Equity Research
Omnicell (OMCL) makes progress in medicare adherence with four new enhancements to its web portal PMAP.
Henry Schein to Offer CAEK's HIPAA Software LayerCompliance
by Zacks Equity Research
Henry Schein (HSIC) inks an agreement to distribute CAEK's HIPAA related software, LayerCompliance.
Here's Why Investors Should Buy Edwards Lifesciences Now
by Zacks Equity Research
Market is upbeat about Edwards Lifesciences's (EW) recent FDA approvals and strong 2017 guidance.
Here's Why Investors Should Buy Align Technology (ALGN) Now
by Zacks Equity Research
Align Technology (ALGN) continues to ride high on robust growth in the Invisalign space.
Intuitive Surgical at 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Share price of Intuitive Surgical (ISRG) reaches a new 52-week high on the back of its new partnership and impressive second-quarter performance.
Medtronic Announces RESOLUTE ONYX ONE-MONTH DAPT Study
by Zacks Equity Research
Medtronic (MDT) announces a clinical trial to evaluate one-month dual antiplatelet therapy in patients implanted with the Resolute Onyx Drug-Eluting Stent during PCI procedures.
Haemonetics Plasma Arm Grows Strong, Blood Center Sluggish
by Zacks Equity Research
Haemonetics (HAE) registers strong top-line growth, banking on Plasma, TEG, hemostasis management as well as a strong cash position. Blood Center drag continues.
Varian (VAR) Rides on Oncology and Proton Therapy Businesses
by Zacks Equity Research
Varian Medical's (VAR) oncology and Proton therapy business' growth prospects remain impressive. However, competition in the radiotherapy space raise concern.
Civitas Solutions (CIVI) Q3 Earnings Beat, Revenues Miss
by Zacks Equity Research
Civitas Solutions (CIVI) gains on strength in Post-Acute Specialty Rehabilitation Services and Adult Day Health services in Q3. However, tweaked full-year 2017 guidance signals dull prospects.
Myriad Genetics (MYGN) Grows on Higher Cancer Test Volumes
by Zacks Equity Research
Myriad Genetics (MYGN) rides high on strength in Molecular Diagnostics with significant contributions from GeneSight. Also, hereditary cancer testing continues to witness sequential growth.
STERIS (STE) Banks on Organic Growth, Competition Intense
by Zacks Equity Research
STERIS' (STE) cost structure is likely to be enhanced through recent organizational changes.
Why Brookdale Senior Living (BKD) Could Be Positioned for a Slump
by Zacks Equity Research
One stock that you may want to consider dropping is Brookdale Senior Living Inc. (BKD), which has witnessed a significant price decline in the past four weeks.
AmerisourceBergen's PharMEDium Slows Down, Competition Rife
by Zacks Equity Research
AmerisourceBergen Corporation (ABC) is facing immediate integration risks from its acquisition of PharMEDium. Also, competition in the generic space raise concern.
STAAR Surgical (STAA) Catches Eye: Stock Moves 8.3% Higher
by Zacks Equity Research
STAAR Surgical Company (STAA) moved big last session, as its shares jumped over 8% on the day.
Zacks.com featured highlights: Gray Television, Align Technology, SolarEdge Technologies, Nova Measuring Instruments and Brooks Automation
by Zacks Equity Research
Zacks.com featured highlights: Gray Television, Align Technology, SolarEdge Technologies, Nova Measuring Instruments and Brooks Automation
BioScrip (BIOS) Gains on CORE Initiatives, Competition Rife
by Zacks Equity Research
The company achieved annualized supply chain improvement since the acquisition of Home Solutions.
OPKO Health (OPK) Posts Narrower-than-Estimated Loss in Q2
by Zacks Equity Research
OPKO Health (OPK) posted lackluster Q2 numbers due to rising operating expenses owing to investment associated to the launch of RAYALDEE, and consistent investment in the pharmaceutical pipeline.